The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Clofazimine: current status and future prospects
Abstract
Clofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-inflammatory activities. However, its efficacy has been demonstrated only in the treatment of leprosy, not in human tuberculosis, despite the fact that this agent is impressively active in vitro against multidrug-resistant strains of Mycobacterium tuberculosis. Recent insights into novel targets and mechanisms of antimicrobial and anti-inflammatory activity coupled with the acquisition of innovative drug delivery technologies have, however, rekindled interest in clofazimine as a potential therapy for multidrug- and extensively multidrug-resistant tuberculosis in particular, as well as several autoimmune diseases. The primary objective of this review is to critically evaluate these recent developments and to assess their potential impact on improving the therapeutic efficacy and versatility of clofazimine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
Large Porous Particles for Pulmonary Drug Delivery
Edwards, D. A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M. L., Mintzes, J., Deaver, D., Lotan, N., & Langer, R. (1997) · Science · doi:10.1126/science.276.5320.1868 · Cited by 1,174
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Trojan particles: Large porous carriers of nanoparticles for drug delivery
Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182233999 · Cited by 546
Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase
Yano, T., Kassovska-Bratinova, S., Teh, J. S., Winkler, J., Sullivan, K., Isaacs, A., Schechter, N. M., & Rubin, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.200501 · Cited by 346
Characterization of curcumin–PVP solid dispersion obtained by spray drying
Paradkar, A., Ambike, A. A., Jadhav, B. K., & Mahadik, K. R. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.11.014 · Cited by 340
Programmes and principles in treatment of multidrug-resistant tuberculosis
Mukherjee, J. S., Rich, M. L., Socci, A. R., Joseph, J. K., Virú, F. A., Shin, S. S., Furin, J. J., Becerra, M. C., Barry, D. J., Kim, J. Y., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15496-2 · Cited by 333
Bacterial membrane lipids in the action of antimicrobial agents
Epand, R. M., & Epand, R. F. (2011) · Journal of Peptide Science · doi:10.1002/psc.1319 · Cited by 332
Sung, J. C., Padilla, D. J., Garcia-Contreras, L., VerBerkmoes, J. L., Durbin, D., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9894-2 · Cited by 244
O'Hara, P., & Hickey, A. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007527204887 · Cited by 242
Peters, K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.77 · Cited by 228
Linezolid for the treatment of multidrug-resistant tuberculosis
Fortún, J., Martín-Dávila, P., Navas, E., Pérez-Elías, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gómez-Mampaso, E., & Moreno, S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki148 · Cited by 225
Bacterial Membranes as Predictors of Antimicrobial Potency
Epand, R. M., Rotem, S., Mor, A., Berno, B., & Epand, R. F. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8062327 · Cited by 172
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic
Chaisson, R. E., Keiser, P. H., Pierce, M. A., Fessel, W. J., Ruskin, J., Lahart, C. J., Benson, C. A., MEEK, K., Siepman, N. Y., & Craft, J. C. (1997) · AIDS · doi:10.1097/00002030-199703110-00008 · Cited by 145
Tocopherol Stabilizes Membrane against Phospholipase A, Free Fatty Acids, and Lysophospholipidsa
Kagan, V. E. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb14913.x · Cited by 144
Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model
Garcia‐Contreras, L., Fiegel, J., Telko, M. J., Elbert, K. J., Hawi, A. A., Thomas, M., VerBerkmoes, J. L., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-06 · Cited by 139
Self-citationShen, G., Wu, B.-D., Hu, S.-T., Lin, C.-F., Wu, K.-M., & Chen, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.008 · Cited by 127
Clinical Pharmacokinetics of Clofazimine: A Review
Holdiness, M. R. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916020-00002 · Cited by 120
Ren, Y. R., Pan, F., Parvez, S., Fleig, A., Chong, C. R., Xu, J., Dang, Y., Zhang, J., Jiang, H., Penner, R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004009 · Cited by 116
van Ingen, J., van der Laan, T., Dekhuijzen, R. P. N., Boeree, M. J., & van Soolingen, D. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.023 · Cited by 104
Bezerra, E. L. M., Vilar, M. J. P., Neto, P. B. D. T., & Sato, E. I. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21358 · Cited by 101
Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin
Fiegel, J., Garcia‐Contreras, L., Thomas, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9381-6 · Cited by 95
Rastogi, N., Goh, K. S., Horgen, L., & Barrow, W. W. (1998) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(98)00044-3 · Cited by 92
Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs
Garcia‐Contreras, L., Sung, J. C., Muttil, P., Padilla, D., Telko, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01471-09 · Cited by 76
Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation
Sung, J. C., Garcia‐Contreras, L., VerBerkmoes, J. L., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01389-08 · Cited by 72
Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug
Sethuraman, V. V., & Hickey, A. J. (2002) · AAPS PharmSciTech · doi:10.1208/pt030428 · Cited by 68
Degradative transport of cationic amphiphilic drugs across phospholipid bilayers
Baciu, M., Sébaï, S. C., Ces, O., Mulet, X., Clarke, J. A., Shearman, G. C., Law, R. V., Templer, R. H., Plisson, C., Parker, C. A., et al. (2006) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2006.1842 · Cited by 67
Anti-staphylococcal activity and mode of action of clofazimine
Oliva, B. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh114 · Cited by 65
Oxidative Stress Increases Susceptibility of Mycobacterium tuberculosis to Isoniazid
Bulatović, V. M., Wengenack, N. L., Uhl, J. R., Hall, L., Roberts, G. D., Cockerill, F. R., & Rusnak, F. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2765-2771.2002 · Cited by 56
Improvement of Albendazole Dissolution by Preparing Microparticles Using Spray-Drying Technique
Alanazi, F. K. (2007) · Scientia Pharmaceutica · doi:10.3797/scipharm.2007.75.63 · Cited by 46
Castañeda-García, A., Do, T. T., & Blázquez, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr165 · Cited by 43
Salem, I. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00236-9 · Cited by 40
Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro
Franzblau, S. G., & O’Sullivan, J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.10.1583 · Cited by 33
Kailasam, S., Wise, D. L., & Gangadharam, P. R. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.273 · Cited by 27
Malone, A. S., Chung, Y.-K., & Yousef, A. E. (2008) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2008.03973.x · Cited by 9
Cited by
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
L-Carnitine and Acylcarnitines: Mitochondrial Biomarkers for Precision Medicine
McCann, M. R., George De la Rosa, M. V., Rosania, G. R., & Stringer, K. A. (2021) · Metabolites · doi:10.3390/metabo11010051 · Cited by 327
Lange, C., Abubakar, I., Alffenaar, J.-W. C., Bothamley, G., Caminero, J. A., Carvalho, A. C. C., Chang, K.-C., Codecasa, L., Correia, A., Crudu, V., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00188313 · Cited by 310
Robbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Metadata
- Authors
- Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A., & Anderson, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-10-20
- Volume
- 67
- Issue
- 2
- Pages
- 290-298
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2125159822
- Cited by
- 351
- References
- 38
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.